Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Nervy trade in London before US data

Thu, 27th Jun 2024 09:00

(Alliance News) - Stock prices in London opened lower on Thursday, despite peers in Europe climbing, with some of the FTSE 100 heavyweights in decline in early trade.

The FTSE 100 index traded 10.85 points lower, 0.1%, at 8,214.48. The FTSE 250 fell just 0.41 of a point at 20,297.69, while the AIM All-Share fell 1.47 points, 0.2%, at 764.45.

The Cboe UK 100 fell 0.2% to 817.15, the Cboe UK 250 lost 0.1% at 17,662.32, and the Cboe Small Companies was down 0.2% at 16,967.50.

In European equities on Thursday, the CAC 40 in Paris was up 0.1% and the DAX 40 in Frankfurt shot up 0.3%.

In China, the Shanghai Composite ended down 0.9%, while the Hang Seng in Hong Kong tumbled 2.1%. The Nikkei 225 in Tokyo closed down 0.8% and the S&P/ASX 200 in Sydney lost 0.3%.

The tepid trade in Asia came despite a decent session in New York on Wednesday. The Dow Jones Industrial Average ended marginally higher, the S&P 500 rose 0.2% and the Nasdaq Composite added 0.4%.

The pound was quoted at USD1.2638 early Thursday, up from USD1.2624 at the time of the London equities close Wednesday. The euro stood at USD1.0694, rising from USD1.0678. Against the yen, the dollar was trading at JPY160.53, down from JPY160.66.

The yen recovered slightly after hitting a 38-year low against the dollar, putting investors on alert for a possible intervention by Japanese authorities.

The Japanese unit's latest retreat came as uncertainty surrounded the Federal Reserve's timetable for cutting interest rates, and the Bank of Japan's caution in tightening monetary policy.

Focus has turned to Tokyo, where Vice Finance Minister Masato Kanda said earlier in the week that authorities were keeping a close eye on movements in forex markets and were ready to step in with yen support 24 hours a day.

Their determination was put to the test after the yen fell to 160.87 per dollar late Wednesday – its weakest since 1986 – as US Treasury yields spiked.

The economic calendar on Thursday has a US gross domestic product reading at 1330 BST, after eurozone consumer confidence at 1000 BST.

On Friday, all eyes will be on the latest core personal consumption expenditures inflation gauge, the Fed's preferred measure.

Focus will also be on political developments, as election campaigns in the UK and France near the finish line, and as US President Joe Biden prepares for a debate against his predecessor Donald Trump.

Biden and Trump square off for a historic US presidential debate Thursday, with the stage set for what could be an inflection point in the 2024 race as millions of voters tune in to the clash of rivals.

In London, DS Smith rose 6.7%. Brazil's Suzano ended the pursuit of International Paper, which is on the verge of sealing a deal to acquire DS Smith.

Suzano last month confirmed its interest in acquiring International Paper. Such a deal would have thrown into doubt International Paper's acquisition of DS Smith.

However, Suzano said Wednesday: "It is important to emphasize that it has always been a condition of Suzano for the completion of this transaction that the engagement between the parties be based on private, confidential, and amicable terms. As it was not possible to proceed in this manner, Suzano has decided to terminate the negotiations."

GSK lost 5.5% on an unfavourable development in the US. The US Centers for Disease Control & Prevention updated its recommendation for the use of respiratory syncytial virus vaccines.

For the upcoming virus season, the CDC recommended everyone aged 75 and older receive a jab. People aged between 60 and 74 are recommended to receive one if they have certain chronic medical conditions, such as lung or heart disease.

There was no recommendation for adults aged under 60, however.

Pfizer shares had fallen 2.0% in New York.

Hurting the FTSE 100, Anglo American fell 2.1%. Berenberg cut the stock to 'sell' from 'hold'. Elsewhere in the mining sector, Rio Tinto and Glencore lost 0.7%.

Back in London, Watches of Switzerland shares rallied 8.4%. It said it is "cautiously optimistic" for its new financial year, after a tricky one just ended.

For the year ended April 28, revenue was largely flat on-year at GBP1.54 billion. Pretax profit, however, fell 40% to GBP92.1 million from GBP154.8 million.

"I am proud of the performance that our team delivered this year in what was undoubtedly a more challenging market. We cemented our position as a leading international luxury watch and jewellery retailer and delivered further market share gains in both the UK and US, driven by our proven, differentiated business model. In particular, our US business went from strength to strength, growing 11% and will soon represent half of group sales," Chief Executive Officer Brian Duffy said.

Looking ahead, the luxury watches seller expects revenue of GBP1.67 billion to GBP1.73 billion for the new year.

It added: "Following the more challenging trading conditions of FY24, we are cautiously optimistic about trading in FY25. The industry as a whole is being more conservative on production, which we believe is a responsible approach to the long-term stability of the luxury watch market."

Outsourcer Serco climbed 6.1% after it upped guidance amid "good progress" in the first half.

It now expects underlying operating profit for 2024 of GBP270 million, its guidance raised from GBP260 million.

The new guidance represents roughly an 8.4% increase from the GBP249 million achieved in 2023.

"We have delivered a good performance in the first half, with progress in improving productivity and the underlying performance of our portfolio," CEO Mark Irwin said. "As we enter the second six months of the year, while mindful of a potential impact internationally from elections in 2024, we remain optimistic about the quality of our pipeline of potential new work to support our medium-term growth targets."

Elsewhere in London, retailer Quiz slumped 24% as its UK sales continue to be hurt by cost of living pressures on consumer spending.

Revenue between the start of April and end of May totalled GBP13.8 million, a decline of around 11% from GBP15.5 million.

"Notwithstanding the continued difficult trading environment in the period, the group is encouraged by a 12% increase in demand for Quiz product in international territories and sales in Quiz stores being broadly comparable year-on-year on a like-for-like basis. UK online traffic has, however, been more severely impacted by the challenging environment and pressures on customers outlined above," the firm added.

Brent oil was quoted at USD84.28 a barrel, up from USD84.21. Gold was quoted at USD2,299.27 an ounce, up from USD2,297.70.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Jun 2024 19:43

IN BRIEF: GSK reaches settlement over Zantac case in Illinois

GSK PLC - London based pharmaceuticals company - Reaches confidential settlement with Martin Gross resolving the case he filed in Illinois state court regarding Zantac. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK. Continues to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.

Read more
27 Jun 2024 17:25

European shares subdued ahead of economic data, French elections; H&M plunges

H&M tumbles after missing quarterly profit forecasts

*

Read more
27 Jun 2024 17:02

London's FTSE 100 slips as investors eye US, UK economic data

FTSE 100 down 0.6%, FTSE 250 adds 0.2%

*

Read more
27 Jun 2024 16:40

GSK shares slide after US health agency narrows scope of RSV shots

GSK shares fall as much as 7%

*

Read more
27 Jun 2024 15:48

London close: Stocks mixed ahead of key UK, US data

(Sharecast News) - London stocks ended Thursday's trading session with a mixed performance as market participants awaited crucial US inflation data and UK GDP figures set to be released later in the week.

Read more
27 Jun 2024 12:05

LONDON MARKET MIDDAY: Tepid trade as eyes on elections, US inflation

(Alliance News) - Stock prices in Europe struggled to make headway heading into Thursday afternoon, with sentiment cautious on the penultimate trading day of the quarter.

Read more
27 Jun 2024 09:58

GSK shares drop as US narrows recommendations for RSV vaccines

(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for the company's Arexvy product.

Read more
26 Jun 2024 22:50

US CDC narrows age recommendation for RSV shots in US

June 26 (Reuters) - The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.

Read more
26 Jun 2024 11:00

US advisers to consider RSV shots as GSK looks to keep market lead

June 26 (Reuters) - A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

Read more
25 Jun 2024 08:25

Merck KGaA shares plunge after cancer drug hopeful fails

FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.

Read more
24 Jun 2024 08:55

TOP NEWS: GSK hails Omjjara approval in Japan; Jemperli review in EU

(Alliance News) - GSK PLC on Monday said it has landed an approval in Japan and also highlighted regulatory progress in the EU.

Read more
24 Jun 2024 07:43

LONDON BRIEFING: Prudential announces buyback; Frasers and THG in deal

(Alliance News) - London's FTSE 100 is called to open lower at the start of the week, with share price falls for major US tech shares, Nvidia included, spooking investors on this side of the Atlantic.

Read more
24 Jun 2024 07:21

GSK reports regulatory progress for Omjjara, Jemperli

(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.

Read more
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.